Human corticotropin-releasing hormone improves overnight FEV1 in nocturnal asthma

J Asthma. 1998;35(3):261-5. doi: 10.3109/02770909809068216.

Abstract

Corticotropin-releasing hormone (CRH) exhibits anti-inflammatory properties independent of its effect on adrenal function. We investigated the safety and effect of CRH in nocturnal asthma, a disease where inflammation is prominent. Five subjects underwent an overnight infusion of placebo on the first night, CRH at a 2.5 micrograms/kg/hr on the second night, and three subjects received CRH at 4.0 micrograms/kg/hr on the third night. A significant improvement occurred in overnight change in forced expiratory volume 1 sec. % (delta FEV1) with CRH (+17.4 +/- 9.1%) as opposed to placebo (-25.9 +/- 7.1%), p = 0.024, CRH was well tolerated. Further research with CRH may clarify the pathophysiology of nocturnal asthma.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Asthma / drug therapy*
  • Asthma / physiopathology*
  • Circadian Rhythm / physiology*
  • Corticotropin-Releasing Hormone / adverse effects
  • Corticotropin-Releasing Hormone / therapeutic use*
  • Female
  • Flushing / chemically induced
  • Forced Expiratory Volume / drug effects*
  • Humans
  • Male
  • Nausea / chemically induced
  • Pilot Projects
  • Single-Blind Method
  • Spirometry

Substances

  • Corticotropin-Releasing Hormone